Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…
The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has…
Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…
KEY BENEFITS AND USESPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with only three agents…
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share…
Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety of…
Market Outlook: Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex challenge for drug…
The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
MARKET OUTLOOK Two of the largest U.S. pharmacy benefit managers, Express Scripts and CVS Health, set in motion a new approach to drug reimbursement by introducing indication-specific pricing (ISP…
Introduction: NASH is characterized by a buildup of excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver damage, leading to fibrosis and subsequently cirrhosis and…